At this week’s Society for Lab Automation and Screening conference in San Diego, the research nonprofit SRI International unveiled SynFini, which it describes as a “fully automated, end-to-end synthetic chemistry system.”
The biggest target market for the platform is drug discovery and development, a space SRI has played in for decades. But SynFini was developed in part with funding from the US Defense Department’s DARPA agency, which is interested in automated synthesis for applications including explosives, polymers, and bioterrorism countermeasures. “We can access virtually any chemistry we set our mind to,” SRI Chief Strategy Officer Nathan Collins says.
SynFini combines three main components: AI-assisted synthetic route design software, an inkjet-based µg- to mg-scale screening and optimization module, and a mg- to kg-scale flow chemistry platform.
The system is still in “beta,” Collins says. SRI uses it in-house on drug leads including for cancer, wound healing, and the flu and on fee-for-service programs with outside clients. Collins says SRI is still working on the business model for SynFini, and a decision on whether or not to offer it as a stand-alone product is a few years off.
Academic researchers are working on similar systems. “Connecting synthesis planning, reaction screening and optimization, and multistep synthesis is a great way to accelerate chemical development,” says Connor Coley, a postdoc at the Broad Institute of MIT and Harvard. Coley was first author on a 2019 Science paper detailing an AI-informed robotic flow chemistry system being developed at MIT (DOI: 10.1126/science.aax1566).
The same DARPA program, “Make-it,” that funded both the MIT and SRI projects also supported the development of Chematica, a synthesis planning software developed by chemist Bartosz Grzybowski and later acquired by MilliporeSigma, which markets it as Synthia. Grzybowski recently published an algorithm that allows Chematica to avoid synthetic methods currently under patent protection.